Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists

28-Sep-2006

Arena Pharmaceuticals, Inc. announced that an investigational niacin receptor agonist that was being developed under its partnership with Merck & Co., Inc. to develop drugs for the treatment of atherosclerosis and other disorders is no longer in development for the treatment of atherosclerosis.

Merck made the decision to discontinue development of MK-0354 following completion of a randomized, double-blind, placebo-controlled Phase 2 clinical trial that evaluated patients with dyslipidemia. Although MK-0354 is no longer being developed for the treatment of atherosclerosis, preclinical studies are underway to explore other possible indications for this compound. Also, exploration of additional investigational niacin receptor agonists for the treatment of atherosclerosis and related disorders will continue under the partnership.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances